Drug intelligence / Profile preview

NCX 226

Development stage: Discontinued
Lead developer: NicOx
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules

Overview

NCX 226 is a novel nitric oxide (NO)-donating molecular entity developed by NicOx for the treatment of pulmonary arterial hypertension (PAH). It is designed as a dual-action compound that releases both bosentan, an endothelin receptor antagonist, and nitric oxide. The drug was shown in preclinical models to have improved efficacy over bosentan alone in preventing airway stiffness and reducing inflammation and oxidative stress associated with pulmonary fibrosis—a condition often linked to PAH. Despite promising preclinical results, development of NCX 226 has been discontinued[1][5][6].

Targets

EDNRA (Endothelin receptor type A)EDNRB (Endothelin receptor type B)sGC (Soluble Guanylyl Cyclase)

Beyond the preview

Go deeper on NCX 226.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NCX 226.

Explore the full profile